Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Hyderabad, 14th February, 2024 ***Press Release***

NATCO records INR 795.6 Crore consolidated revenue and INR 212.7 Crore of profit, after tax, for the Third Quarter, FY2024

Hyderabad based NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has recorded consolidated total revenue of INR 795.6 Crore, for the Third quarter ended on 31st December, 2023, as against INR 513.3 Crore for the same period last year, reflecting a growth of 55%. The net profit for the period, on a consolidated basis, was INR 212.7 Crore as against INR 62.3 Crore during the same period last year.

The company has shown strong growth across businesses compared to last year and is confident of its strategy going forward. For 9 months ending December 31st, 2023, the company recorded total revenue of INR 3016.6 Crore as against INR 1884.8 Crore for same period last year. Similarly, the net profit for 9 months, the company recorded INR 1002.0 Crore as against INR 439.5 Crore in the same period last year.

Segmental Revenue Split (All Figures in INR Crore)-

Segment	Revenue, Q3 FY24	Revenue, Q2 FY24	Revenue, Q3 FY23
API	46.3	77.8	42.6
Formulations, Domestic	99.4	102.5	101.1
Formulations, Exports (incl. Profit Share & Foreign Subs)	605.6	792.3	333.7
Other Operating income & non-operating income	30.2	32.4	26.0
Crop Health Sciences (CHS)	14.1	55.8	9.9
TOTAL	**795.6**	**1060.8**	**513.3**

The Board of Directors has declared Third interim dividend of INR 1.25 per equity share, for FY 2023-24.

For Natco Pharma Limited

CHEKURI VENKAT RAMESH
Digitally signed by CHEKURI VENKAT RAMESH
Date: 2024.02.14 14:55:46 +05'30'

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer